$CAPR

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week - Capricor Therapeutics (NASDAQ:CAPR), Champions Oncology (NASDAQ:CSBR)

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.

Original reporting
Benzinga · Vishaal Sanjay
Published Sep 3, 2025, 10:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2025, 11:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week - Capricor Therapeutics (NASDAQ:CAPR), Champions Oncology (NASDAQ:CSBR) — source image
Decision brief

The 30-second read

$CAPRBearishMed
01

Why it matters

The fading momentum suggests increased volatility and potential downside risk in the near term.

02

Market read

The recent weakness in selected biotech stocks reflects sector-specific sentiment shifts, with potential implications for related small-cap biotech firms.

03

What to watch

Potential upcoming catalysts or news that could reverse current sentiment, such as clinical trial results or partnership announcements.

Timing: Short to medium term (1-2 weeks)

Background

Recent decline in momentum scores indicates waning investor confidence in these biotech stocks.

Company-level read

Ticker impact

$CAPRBearishMedium confidence
Context

Moderate relevance as a biotech stock with somewhat-bearish sentiment, indicating potential weakness.

Expected impact

Potential further decline of 5-10% over the next 1-2 weeks if current trends persist.

Evidence & confidence

Negative sentiment and declining momentum scores support cautious bearish outlook.

$CSBRBearishMedium confidence
Context

Moderate relevance with somewhat-bearish sentiment, indicating possible near-term weakness.

Expected impact

Expected decline of approximately 3-7% in the near term if current sentiment persists.

Evidence & confidence

Negative sentiment and fading momentum scores suggest cautious bearish stance.

Market effects

Weakness in biotech stocks may lead to broader sector caution, especially among small-cap biotech firms.

Limited regional impact; primarily affects US biotech sector.

Minimal direct global impact; sector-specific dynamics.

Counterpoint

The decline may represent a temporary correction; some investors might view this as a buying opportunity if fundamentals remain strong.

Key entities

  • Capricor Therapeutics

    A biotech firm focused on developing cell and gene therapies.

  • Champions Oncology

    A provider of cancer research services and solutions.

  • LivaNova PLC

    A medical device company with operations in the healthcare sector.

Related articles

$CSBRMed

CHAMPIONS ONCOLOGY, INC. (CSBR): Results of Operations and Financial Condition

CHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Revenue of $15.2 Million Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000 Hackensack, NJ – September 10 , 2026 – Champions Oncology,

$CAPRMedAI 8/10

CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?

Capricor Therapeutics (CAPR) stock surged 144% in a month due to positive phase III data for its cell therapy deramiocel, renewed FDA engagement, and a refined regulatory pathway. The FDA accepted additional data and extended the PDUFA date to November 22, 2026, focusing on upper-limb function. Investors are optimistic despite regulatory risks, with the upcoming FDA decision being a major catalyst.

$CAPRMedAI 8/10

Could New Long-Term Data Support Capricor’s Duchenne Therapy?

Capricor Therapeutics (NASDAQ:CAPR) received a 3-month FDA review extension for deramiocel, its Duchenne muscular dystrophy therapy, after submitting new 24-month data. The FDA accepted the submission, citing high unmet medical need. The company shifted focus to upper limb function, where it reported positive trial results. Shares rose 15% to $7.25 post-announcement.

$CAPRHigh

Capricor Therapeutics stock rises on Piper Sandler upgrade

Capricor Therapeutics (CAPR) shares rose 5.5% premarket after Piper Sandler upgraded it to Overweight and raised its price target to $25. The upgrade follows an FDA review extension for deramiocel, with data showing a 4.55% difference in upper limb function improvement. Piper Sandler notes potential upside if approved by the November 22 PDUFA date. Capricor had $238 million in cash at Q2 fiscal 2026.

$CAPRMedAI 8/10

A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path

Capricor Therapeutics (CAPR) is shifting its focus to a narrower upper limb skeletal muscle indication after an FDA advisory committee rejected its initial cardiomyopathy treatment bid. The company reported Q2 net loss of $40.7M, with cash reserves declining to $237.9M. Positive data from the HOPE-3 trial supports the new strategy, but regulatory timelines are extended. The FDA will review the amended BLA, and Capricor is exploring regulatory paths in Europe and Japan.

$CAPRHigh

Capricor Therapeutics stock surges on Oppenheimer upgrade

Capricor Therapeutics Inc (CAPR) shares rose 15.7% after Oppenheimer upgraded the stock to Outperform with a $54 price target. The FDA accepted new material for its deramiocel treatment, setting a new PDUFA date of November 22. The company plans to disclose 24-month trial data before this date. Oppenheimer cited the FDA's positive signal and potential approval prospects.